LONDON, August 21, 2014 /PRNewswire/ --

Allergic rhinitis drugs - new study showing you trends, R&D progress, and predicted revenues

Where is the allergic rhinitis drugs market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 274-page report provides 204 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Maureen Jenkins, Director of Clinical Services, Allergy UK
• Tonya Winders, President & CEO, Allergy and Asthma Network Mothers of Asthmatics (AANMA)
• Jonathan Bernstein, Professor, University of Cincinnati College of Medicine
• Hazel Econs, Financial & Marketing Director, Allergy Medical UK
• Kimihiro Okubo, Chairman and Professor, Nippon Medical School

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you will see forecasts to 2024 for these five submarkets:
• Oral antihistamines
• Intranasal corticosteroids
• Intranasal antihistamines
• Immunotherapy
• Other drugs.

Additionally, our new study provides global sales forecasts by volume for the intranasal corticosteroids and intranasal antihistamines submarkets, including individual global sales forecasts by volume for the leading drugs in these submarkets from 2014-2024.
 
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 26 products, including these brands:
• Nasonex
• Allegra/Allegra-D/Allegra OTC
• Zyrtec/Zyrtec D
• Claritin/Claritin OTC
• Astepro
• Avamys/Veramyst
• Xyzal
• Allelock
• Staloral
• Clarinex

Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, China, Mexico and Brazil, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Leading companies and potential for market growth
Overall world revenue for allergic rhinitis drugs will reach $11.3bn in 2014, our work forecasts. We predict revenue growth from 2014 to 2024. Rising demand for allergic rhinitis drugs, expanding healthcare coverage, economic recovery and the growth of the immunotherapy submarket will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these:
• ALK-Abelló
• GSK
• Johnson & Johnson (J&J)
• Kyowa Hakko Kirin
• Merck & Co. (Merck)
• Sanofi
• Stallergenes
• UCB.

A company profile gives you the following information:
• Revenue forecast for allergic rhinitis drugs from 2014 to 2024
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas:
• Oral antihistamines
• Intranasal corticosteroids
• Immunotherapy
• Other progress in allergic rhinitis.

Our study also discusses these agents and technologies, among others:
• Subcutaneous immunotherapy
• Sublingual immunotherapy tablets
• Oral antihistamines
• Intranasal corticosteroids
• Novel small molecules including toll-like receptor antagonists.

Allergic rhinitis R&D is strong in immunotherapy. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the allergic rhinitis drugs industry?
Our new report discusses issues and events affecting the allergic rhinitis drugs market. You will find discussions, including qualitative analyses:

• Increasing demand for allergic rhinitis drugs due to increasing prevalence
• A strong immunotherapy R&D pipeline
• Patent expiry and generic competition
• Growth areas such as immunotherapy and combination drugs
• Rx-to-OTC switching
• Pricing and reimbursement issues

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

How the Allergic Rhinitis Drugs Market Forecast 2014-2024: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines report helps you
In summary, our 274-page report gives you the following knowledge:
• Revenues forecast to 2024 for the world allergic rhinitis drugs market and 5 product categories (therapeutic classes) - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 12 national markets - US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World
• Assessment of 8 leading companies - hear about products, results and strategies including revenue forecasts for allergic rhinitis drugs to 2024
• Predicted revenues of 26 leading drugs to 2024 - see potentials of top products
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the allergic rhinitis drugs market and leading companies. You find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44(0)20-7336-6100

Or click on https://www.visiongain.com/Report/1306/Allergic-Rhinitis-Drugs-Market-Forecast-2014-2024

Companies Listed in this Report
ActoGeniX
Adamis Pharmaceuticals
Alcon (subsidiary of Novartis)
Alembic
Alergo Pharma (acquired by Stallergenes)
ALK-Abelló
Allergologisk Laboratorium København (ALK) (now ALK-Abelló)
Allergology Laboratory (now ALK-Abelló)
Allergopharma (acquired by Merck Group)
Allergy Medical UK
Allergy Therapeutics
Allermed Laboratories (acquired by Greer)
Almirall
Altana Pharma (acquired by Nycomed)
Ampio
Anergis
Antigen Laboratories (acquired by Greer)
Apotex
Archimedes Pharma (acquired by Kyowa Hakko Kirin)
Ares Life Sciences
Aspen Pharmacare
AstraZeneca
Atopix Therapeutics
Aventis (merged into Sanofi)
Barr Laboratories (subsidiary of Teva)
Bausch + Lomb (acquired by Valeant)
Bayer
Belcher Pharmaceuticals
Bio-Medical Services (acquired by ALK-Abelló)
Biopol Laboratory (acquired by ALK-Abelló)
Biotech Tools
Biotechnology Value Fund
BMP Sunstone (part of Sanofi)
Boehringer Ingelheim
Caremark CVS
Catalent Pharma Solutions
Celltech (part of UCB)
Celsus Therapeutics
Center Laboratories (acquired by ALK-Abelló)
Chattem (part of Sanofi)
Cipla
Circassia Pharmaceuticals
Daewon
Dainippon Sumitomo
DBV Technologies
Dongkook
Dr. Reddy's Laboratories
Eddingpharm
Eleventa LLC
Entod
Express Scripts
Fountain Biopharma
GenMont Biotech
Genzyme (part of Sanofi)
Glycomar
Glycores
Greer Laboratories (acquired by Ares Life Sciences)
Grifols
GSK (GlaxoSmithKline)
HAL Allergy
Hanlim
Hi Tech Pharma
Hisamitsu Pharmaceutical Co.
Hoechst AG
Human Genome Sciences (acquired by GSK)
Inspire Pharmaceuticals (acquired by Merck)
Institut Mérieux
Intas Pharmaceuticals
Janssen Pharmaceutica (subsidiary of Johnson & Johnson)
Johnson & Johnson (J&J)
Jubilant HollisterStier
Kalypsys
Keldman Healthcare
Kyowa Hakko Kirin
Laboratorios Leti
Leti Pharma (subsidiary of Laboratorios Leti)
Lupin
McNeil Consumer Healthcare (subsidiary of Johnson & Johnson)
Meda
Medley (acquired by Sanofi)
MedPointe Inc.
Merck & Co. (Merck)
Merck Group (Merck-Serono; Merck KGaA)
Merck Sharp & Dohme (MSD) (subsidiary of Merck)
Mitsubishi Tanabe
Mylan
Nektar Therapeutics
Nelco Laboratories (acquired by ALK-Abelló)
Nippon Paper Group
Novartis
Nuvo Research
Nycomed (subsidiary of Takeda)
Omega Pharma
Ono Pharmaceutical
Oxagen Limited
Perrigo
Pfizer
Prestige Brands
Prostrakan (subsidiary of Kyowa Hakko Kirin)
Reckitt Benckiser
Roxane Laboratories (subsidiary of Boehringer Ingelheim)
Sam Chun Dang
Sam-A
Sandoz (generics division of Novartis)
Sanofi
Sanofi Pasteur (part of Sanofi)
Schering-Plough (merged into Merck)
Schwarz Pharma (part of UCB)
Sepracor (now Sunovion Pharmaceuticals)
Shionogi
Stallergenes
Stiefel Laboratories (part of GSK)
Sun Pharma
Sunovion Pharmaceuticals (subsidiary of Dainippon Sumitomo)
Synthélabo (merged into Sanofi)
Synthes Inc. (acquired by Johnson & Johnson)
Takeda
Teva
Torii
Trimel Pharmaceuticals
Ube Industries
UCB
VentiRx
Verona Pharma
Vespa Laboratories (acquired by ALK-Abelló)
ViiV Healthcare (GSK-Pfizer joint venture)
WellPoint Healthcare
Wockhardt
Zeltia
Zentiva (acquired by Sanofi)
Ziarco Pharma

Other Organisations Mentioned in this Report
Allergy & Asthma Network Mothers of Asthmatics (AANMA)
Allergy UK
American Academy of Allergy, Asthma and Immunology (AAAAI)
Bank of Spain
China Food and Drug Administration (CFDA)
Consumer Healthcare Products Association (CHPA) (US)
Department of Pharmaceuticals (India)
European Medicines Agency (EMA)
Haute Autorité de Santé (France)
Health and Social Care Information Centre (UK)
Health Canada
Imperial College London
Japanese Society of Allergology
Ministry of Agriculture, Forestry and Fisheries (Japan)
Ministry of Food and Drug Safety (MFDS) (South Korea)
Ministry of Health, Labour and Welfare (MHLW) (Japan)
National Health Service (NHS) (UK)
National Pharmaceutical Pricing Authority (India)
Nippon Medical School
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pollen UK
Rashtriya Swasthya Bima Yojana (India)
Servicio Sanitario Nazionale (SSN) (Italy)
Unified Health System (SUS) (Brazil)
United States Food and Drug Administration (FDA)
Université Libre de Bruxelles
University of Cincinnati
University of Leuven
US Securities and Exchange Commission (SEC)
World Allergy Organization (WAO)
World Health Organization (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com or call Tel : +44(0)20-7336-6100.